Mayo Clinic Identifies TRAILshort as T-Cell Brake Across 5 Cancers and HIV
Updated
Updated · BIOENGINEER.ORG · Aug 3
Mayo Clinic Identifies TRAILshort as T-Cell Brake Across 5 Cancers and HIV
1 articles · Updated · BIOENGINEER.ORG · Aug 3
Summary
Journal of Clinical Investigation data show TRAILshort directly shuts down T-cell receptor signaling, giving cancer cells and pathogens a shared way to evade immune attack.
SHP-1 appears to drive that effect: the protein variant activates the phosphatase, stripping key phosphate signals before T cells can fully activate, produce cytokines or kill targets.
Preclinical blocking experiments restored T-cell signaling and improved attacks on diseased cells, while removing or inhibiting TRAILshort also revived CAR-T tumor control.
The mechanism was detected in melanoma, lung, breast, pancreatic and ovarian cancers plus Hodgkin lymphoma, and was also linked to HIV, COVID-19, tuberculosis and hepatitis C.
That breadth makes TRAILshort a potential drug target and biomarker for immunotherapy resistance, though researchers still need to test safety risks such as excess inflammation or autoimmunity.
Will disabling the TRAILshort protein supercharge immunotherapies, or could it unexpectedly unleash dangerous autoimmune reactions within the human body?
How did a protein variant found in HIV research become the missing link to understanding cancer's ability to evade the immune system?